Undisclosed TCR-T Program(s)

About Pan Cancer T

Pan Cancer T is a private, preclinical-stage biotech pioneering next-generation TCR-T cell therapies for solid tumors. The company leverages a proprietary platform to discover optimal-affinity TCRs against unique, cancer-specific intracellular antigens and engineers T cells for improved persistence and function. With a seasoned leadership team experienced in TCR development and cell therapy manufacturing, the company is building a pipeline targeting high-need oncology indications where current cell therapies have limited efficacy. Its strategy focuses on overcoming key barriers in solid tumor treatment, including target identification and the immunosuppressive tumor microenvironment.

About Mongoose Bio

Mongoose Bio is a private, early-stage clinical company spun out of MD Anderson Cancer Center in 2023, based on foundational research by Dr. Cassian Yee. The company's core innovation is an epigenetic reprogramming platform that engineers long-lived central memory T cells (Tcm) with defined TCRs against validated, highly immunogenic tumor targets to treat solid tumors. Led by an experienced CEO with a track record in cell therapy and biopharma, Mongoose Bio is positioned to address the significant unmet need in solid tumor oncology by aiming to improve the persistence, safety, and efficacy profile of adoptive T cell therapies. The company is pre-revenue and focused on advancing its proprietary platform and pipeline through clinical development.

Therapeutic Areas

Other Solid Tumors Drugs